Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM) from its SEC filings: 2025 revenue $638.5 million (+66% vs the year before), net margin -29%, free cash flow -$93.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $638.5 million |
| Revenue growth | +66% |
| Net income | -$183.2 million |
| Net margin | -28.7% |
| Free cash flow | -$93.9 million |
| Diluted EPS | $-3.68 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +46% |
| Cash | $319.9 million |
| Long-term debt | $118.0 million |
| Share count, 1 year | +5% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.